MedMira Wins Exclusive Right to Sell Rapid HIV Tests in China's Guizhou Province Represents Upwards of 1.5 Million Tests per Year for Province's Blood Banks HALIFAX, June 1 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has won a government tender to supply rapid HIV tests to blood collection centres in the province of Guizhou in the People's Republic of China. Guizhou is one of China's largest blood plasma producers, supplying over 30% of the country's annual requirement of plasma units. Selected based on its high quality performance, MedMira's MiraWell(R) Rapid HIV Test (MiraWell(R)) will be the only rapid HIV test permitted to be used in Guizhou's blood collection centres. This represents the first time rapid HIV tests were considered for selection in Guizhou's annual tender process for diagnostic tests. MedMira anticipates supplying up to 1.5 million MiraWell(R) tests over the next year with the initial shipment within the next 90 days. Official documents and results of the tender are available in Chinese at http://gz.emedchina.net/view.asp?id(equal sign)32764&catalogid(equal sign)38. "We are extremely pleased to play such a significant role in Guizhou Province's groundbreaking decision to introduce rapid HIV tests for general screening in blood banks. Their acceptance and use of our MiraWell(R) Rapid HIV Test is the highest seal of approval for the quality and performance of our product," said Hermes Chan, president and chief operating officer of MedMira. "MedMira executives and the Provincial blood screening representatives will meet later this month to discuss the logistics of the orders during the tender period." Guizhou's blood collection centres are located throughout the province in both rural and urban areas, where many of MiraWell(R)'s key features (reliable results, easy-to-use and interpret, with no refrigeration required) are essential. MiraWell(R) is ideal for blood collection screening, providing HIV test results in just 3 minutes. MiraWell(R) was recently ranked the number one rapid HIV test in overall performance in an independent 2004 China National Center for Disease Control (CDC) report. MedMira is the only Canadian company approved by the China State Food and Drug Administration (SFDA) to import its rapid HIV test into the country. About Guizhou Province, P.R. China Situated mostly on a high mountain plateau, Guizhou is rarely visited by outsiders. It is home to at least 30 ethnic minorities, including the Miao and the Dong. It has the highest annual rainfall in China and a mild climate, and although scenic, most of the land is not conducive to extensive farming. Poverty among the province's 35 million people is widespread, but manufacturing industries are growing, particularly mining of the region's rich deposits of mercury, coal and phosphate. It is a leader in forest products. The capital is Guiyang. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(R) Rapid HIV Tests, respectively. MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail:

Copyright